uniQure (NASDAQ:QURE) Upgraded by Wall Street Zen to "Hold" Rating

Key Points

• Wall Street Zen upgraded uniQure from “Sell” to “Hold,” while the broader analyst consensus remains “Moderate Buy,” based on 13 Buy, three Hold, and one Sell rating.
• Analysts have sharply raised price targets, with an average target of $65.00 compared with the reported share price of $48.62; individual targets range from $46 to $80.
• uniQure reported a quarterly loss of $1.22 per share, missing estimates by $0.40, despite revenue of $5.84 million exceeding expectations; insiders have sold approximately $16.8 million of stock over the past 90 days.

uniQure (NASDAQ:QURE - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday.

Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald upgraded shares of uniQure from a "neutral" rating to an "overweight" rating and set a $61.00 price target on the stock in a research note on Wednesday, June 17th. Royal Bank Of Canada increased their price target on uniQure from $35.00 to $65.00 and gave the stock an "outperform" rating in a report on Thursday, June 18th. HC Wainwright lifted their price objective on uniQure from $50.00 to $80.00 and gave the company a "buy" rating in a report on Monday, June 29th. Leerink Partners boosted their target price on shares of uniQure from $36.00 to $70.00 and gave the stock an "outperform" rating in a research report on Thursday, June 18th. Finally, The Goldman Sachs Group upped their price target on uniQure from $14.00 to $46.00 and gave the stock a "neutral" rating in a report on Thursday, June 18th. Thirteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $65.00.

uniQure Stock Up 3.3%

Shares of NASDAQ:QURE opened at $48.62 on Friday. uniQure has a 1 year low of $8.73 and a 1 year high of $71.50. The firm's 50-day moving average is $41.26 and its two-hundred day moving average is $27.86. The firm has a market capitalization of $3.37 billion, a PE ratio of -12.12 and a beta of 0.92. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01.

uniQure (NASDAQ:QURE - Get Free Report) last released its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.40). The company had revenue of $5.84 million during the quarter, compared to analysts' expectations of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same quarter last year, the business posted ($0.69) earnings per share. Analysts predict that uniQure will post -3.74 EPS for the current year.

Insider Activity at uniQure

In other uniQure news, Director Madhavan Balachandran sold 11,685 shares of the business's stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total transaction of $526,526.10. Following the transaction, the director owned 43,254 shares in the company, valued at $1,949,025.24. The trade was a 21.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 30,000 shares of the company's stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $46.42, for a total transaction of $1,392,600.00. Following the completion of the transaction, the insider owned 148,235 shares of the company's stock, valued at $6,881,068.70. This trade represents a 16.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 388,229 shares of company stock valued at $16,817,099 over the last 90 days. 4.65% of the stock is currently owned by insiders.

Hedge Funds Weigh In On uniQure

A number of hedge funds have recently bought and sold shares of the company. Hennion & Walsh Asset Management Inc. boosted its stake in uniQure by 107.3% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 142,113 shares of the biotechnology company's stock valued at $6,546,000 after acquiring an additional 73,566 shares during the period. Kalehua Capital Management LLC bought a new position in shares of uniQure in the first quarter worth $4,760,000. UBS Group AG increased its stake in uniQure by 139.7% during the 4th quarter. UBS Group AG now owns 491,454 shares of the biotechnology company's stock valued at $11,760,000 after buying an additional 286,465 shares during the period. Voss Capital LP increased its stake in shares of uniQure by 68.0% during the fourth quarter. Voss Capital LP now owns 210,000 shares of the biotechnology company's stock valued at $5,025,000 after acquiring an additional 85,000 shares during the period. Finally, Jennison Associates LLC raised its stake in shares of uniQure by 37.2% in the 4th quarter. Jennison Associates LLC now owns 1,371,190 shares of the biotechnology company's stock worth $32,813,000 after buying an additional 371,706 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source